Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is NN9662 (Triple)?
Plain language first. The technical label stays, but it never stands alone.Overview
There are two things to get straight about this one, and the first is which drug it is. Novo Nordisk has two triple agonists in development, both described in the press as Novo's triple agonist, and they are not the same molecule. The better-known one, UBT251, hits GLP-1, GIP and glucagon, and it has published weight-loss results that this site already covers. This one hits GLP-1, GIP and amylin instead. Swapping glucagon for amylin is a real difference in how a drug works, and almost all the coverage collapses the two. The second thing is how little is known. Novo has described the targets exactly once, in a single phrase in one annual report table, and has not repeated it since, including in its November 2026 materials where the compound appears as an unlabeled line in a milestone list. Six trials have run or are running, two of them finished, and not one result has been released. There has not even been a press release about it.
NN9662 is an investigational obesity and type 2 diabetes compound from Novo Nordisk, appearing in company documents as Triple with the project code NN9662 and in trial records as NNC0662-0419. Novo's 2025 annual report describes it in a single phrase, GLP-1/GIP/amylin, in its phase 2 obesity table. That is the sponsor's only public statement of mechanism, and it has not been repeated in any 2026 document. No molecular format has been stated: the registry holds no record, no nonproprietary name exists, and while a Novo patent family describes a single-chain GLP-1, GIP and amylin receptor tri-agonist peptide of roughly 66 to 80 residues, none of those filings names this compound code. Six subcutaneous trials are registered across obesity and type 2 diabetes, and no efficacy or safety figure has ever been published.
What it's used for
Investigational for obesity and for type 2 diabetes. It is not approved anywhere, is not sold, and no results have been published.
How does NN9662 (Triple) work?
What it does in the body, and where.The mechanism is the whole reason this page exists, and not because it is exotic. It is because one receptor out of three is reported wrongly almost everywhere, and the error turns this drug into a different drug.
- 01Three targets, and the one that is in disputeGLP-1 reduces appetite and slows the stomach. GIP is a second gut hormone receptor that appears to improve weight loss when added to GLP-1, and that is the basis of the dual agonist class. The third target is where the confusion lives. Novo's annual report says amylin, the pancreatic fullness hormone this site covers in ten other pages. Much of the secondary literature says glucagon instead, because glucagon is the third target of the other triple agonists people know.
- 02Why amylin against glucagon is a real differenceGlucagon raises energy expenditure and mobilizes stored fuel, and it also pushes blood sugar up, so glucagon-containing agonists need careful handling in diabetes. Amylin does close to the opposite on glucose: it blunts the glucagon response after a meal and adds a separate fullness signal. So a GLP-1, GIP and amylin molecule and a GLP-1, GIP and glucagon molecule are not two versions of one idea. They are different bets about what a third mechanism should add.
- 03Novo's two triples, side by sideUBT251, in-licensed and carried on this site under code NN9559, is described by Novo as a GLP-1, GIP and glucagon triple receptor agonist, and it has published phase 2 weight-loss data. This one, Novo's internal program, targets GLP-1, GIP and amylin. In November 2026 Novo's head of development named both in one breath and distinguished them, saying the company anticipates phase 1/2 results for both of its tri-agonists in the first half of 2027. On the site's own pages the difference now shows in the diagram: the receptor panel lists the third target.
- 04What format the molecule takes, and why we will not state itA Novo patent family filed three weeks before this compound's first-in-human trial describes a GLP-1, GIP and amylin receptor tri-agonist built as a single-chain peptide backbone of roughly 66 to 80 residues, with a GLP-1 and GIP co-agonist segment, a peptide linker and an amylin receptor agonist segment, and it expressly contrasts that with the separate-compositions approach used for cagrilintide plus semaglutide. Every trial record lists one investigational product with one matched placebo, never two co-administered agents, and dosing is weekly by subcutaneous injection, in one study through a pen injector. All of that points one way. None of it closes the question, because no patent names this compound code and no Novo document states the format. The registry holds no record and there is no nonproprietary name.
- 05What the trials are actually askingRead the six records together and the program's preoccupation is tolerability rather than potency. The obesity dose-escalation trial's primary outcome is a count of gastrointestinal adverse events across 39 weeks, with weight change secondary. The first-in-human study measured adverse event counts and exposure. A dedicated study checks the effect on an oral contraceptive's absorption and on gastric emptying, the standard question for a drug that slows the stomach. That is a program trying to find a dose people can stay on.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Which drug this is, and which it is not
none- RegulatoryNovo's 2025 annual report describes it in one phrase: GLP-1/GIP/amylin. That is the sponsor's only public statement of mechanism.
- RegulatoryUBT251, on this site under code NN9559, is Novo's other triple and targets GLP-1, GIP and glucagon. In November 2026 management named both and distinguished them explicitly.
- RegulatoryThe identity chain is sponsor-confirmed: every NNC0662-0419 trial carries an organization study ID beginning NN9662, and Novo's own trial pages serve the compound code under those IDs.
- lab-analysisNo card on this site previously described a GLP-1, GIP and amylin molecule. Retatrutide's third target is glucagon.
Six trials, roughly 770 participants, and no published number
Investigational- Human trialTwo phase 1 studies are complete, 100 participants each, and neither has a results section posted.
- Human trialThree phase 2 trials are running: 224 in obesity dose-finding, 233 in obesity dose escalation against semaglutide, and 270 recruiting in type 2 diabetes against semaglutide across 63 sites in 10 countries.
- Human trialA sixth study, 41 participants, tests the effect on an oral contraceptive's absorption and on gastric emptying.
- No dataA literature search on both compound codes returned no publications at all. There has never even been a press release about this compound, a weaker evidence base than press-release-only.
- No dataNo dose amount appears in any of the six records.
The format question, still open
none- lab-analysisA Novo patent family filed three weeks before the first-in-human trial describes a single-chain GLP-1, GIP and amylin receptor tri-agonist peptide of roughly 66 to 80 residues, built as a co-agonist segment, a linker and an amylin segment, and contrasts it with the separate-compositions approach of cagrilintide plus semaglutide.
- No dataNo patent in that family names this compound code, so the link is circumstantial: same company, same three receptors, same timing.
- RegulatoryThe FDA substance registry returns nothing for either code against a working control, so there is no registry classification, no chain count and no residue count. No nonproprietary name exists.
- lab-analysisEvery trial lists one product and one matched placebo, dosing is weekly and subcutaneous, and one study uses a pen injector. All consistent with a single peptide and none of it a sponsor statement.
How it gets reported wrongly, with the specific errors
none- No dataA major drug database's English page for this compound lists its targets as glucagon, GIP and GLP-1 receptors, where Novo says amylin.
- No dataThe same vendor's Chinese-language blog says GLP-1, GIP and amylin, so one company publishes both answers for the same compound.
- No dataA pipeline tracker lists Novo Triple and UBT251 as a single asset with glucagon as the third target. They are separate assets on Novo's own slides.
- No dataAnother database calls it a small molecule medicine. That cannot be right for a compound of this receptor profile and weekly injected dosing.
- No dataTrade coverage of the triple agonist race covers only UBT251 as Novo's triple, and that is the route by which this compound's amylin profile gets overwritten.
One number does most of the damage. The 19.7% weight loss widely attributed to Novo's triple agonist belongs to UBT251, from a 24-week phase 2 trial in China, and it is reported on UBT251's own page here. This compound has never published a weight figure at all. The 13.1% at 12 weeks that also circulates is amycretin. The second error is the third receptor: Novo's annual report says amylin, while a major drug database's English entry, a pipeline tracker and most trade coverage say glucagon, usually because they have merged this compound with UBT251. The same database contradicts itself, publishing amylin in its Chinese-language writing and glucagon in its structured English data. The third error is molecular class: at least one database describes this as a small molecule medicine, a description that does not fit a weekly subcutaneous injection against three peptide hormone receptors. The fourth is subtler and comes from reading the trial records: GLP-1, GIP and amylin do appear in them, but only in exclusion criteria listing prior treatments a participant must not have had, so they describe who may enroll rather than how the drug works. Finally, the trial that sets this compound against semaglutide looks like a head-to-head on weight and is not: its primary outcome is a count of gastrointestinal adverse events.
The published record
Papers about NN9662 (Triple)
Searched: NN9662, NNC0662-0419.
Left out: UBT251 (THE critical rejection, and the dominant public error. Novo's OTHER triple agonist, in-licensed, already on this site under code NN9559, targeting GLP-1/GIP/GLUCAGON where this one targets GLP-1/GIP/AMYLIN. Novo's own slides list them as separate line items and management named and distinguished both on the Nov 4 2026 call. A pipeline tracker treats Novo Triple and UBT251 as ONE asset, and trade coverage of the triple agonist race covers only UBT251 as Novo's triple, which is how this compound's amylin profile gets overwritten); NN9559 (UBT251's Novo project code, one digit family from this compound's NN9662); 19.7% (the weight-loss figure that belongs to UBT251 from its 24-week Chinese phase 2, confirmed in Novo's own Capital Markets Day deck. This compound has published NO weight figure at all, so any appearance of 19.7% on its page is contamination); retatrutide (the best-known triple agonist, with its own slug and a large literature. Its third target is GLUCAGON, not amylin, so it is the other kind of triple); amycretin (now zenagamtide, Novo's GLP-1 plus amylin DUAL agonist with its own slug. Its 13.1%-at-12-weeks phase 1 figure also circulates loosely and is not this compound's); cagrisema (a fixed-dose COMBINATION of two molecules with its own slug. Novo uses the phrase fixed-dose combination for it and pointedly does not use it for this compound, which is part of why the format question stays open); triple agonist (the generic class term, returning retatrutide, UBT251, mazdutide and efocipegtrutide. Novo's internal nickname for this asset is literally Triple, which makes keyword search on the phrase useless); GLP-1 (the receptor class term, tens of thousands of records).
6 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
6 registered trials · none with posted results
Furthest stage reached: Phase 2, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.
At a glance
Four things to know about NN9662 (Triple)
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Not published
How much, and do you cycle it?
The range, and whether you take breaks.No dose disclosed in any trial record, once weekly. Continuous weekly dosing, with a step-up at the start Trial dose
Every trial doses once weekly for the study's full length, with dose escalation at the beginning. One phase 2 trial exists specifically to compare escalation regimens. That is a ramp rather than a cycle, and no planned break appears in any record.
Not publishedNo figure
No half-life has been reported. Two phase 1 studies measured exposure, including one comparing Japanese, Chinese and non-Asian participants, and neither has posted results. Once-weekly subcutaneous dosing implies a half-life on the order of days, an inference from the dosing interval and not a published value.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
NN9662 (Triple) has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Attributing the widely quoted 19.7% weight loss to this compound, since that figure belongs to UBT251, Novo's other triple agonist, and is reported on its own page here
- Treating it as retatrutide's equivalent, because retatrutide's third target is glucagon and this one's is amylin
- Repeating the description of it as a small molecule that appears in at least one drug database, since a compound of this receptor profile and dosing is not a small molecule
- Reading the GLP-1, GIP and amylin mentions in its trial records as its mechanism, because every one of them sits in exclusion criteria describing prior therapies a participant must not have taken
Stop and get help
- This exists only inside Novo-run trials, so there is no dose anyone can take or stop outside one
- Participants follow their trial's own stopping rules, and those are not public
Common effects
- Nothing has been published. One phase 2 trial is built around counting gastrointestinal events.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is NN9662 (Triple) approved?
And where the numbers on this page come from.No. NN9662 (Triple) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked6 November 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesNovo Nordisk annual report 2025, innovation and therapeutic focusClinicalTrials.gov, the phase 2 obesity dose-finding trial (NCT07184632)ClinicalTrials.gov, the phase 2 type 2 diabetes dose-finding trial (NCT07415954)ClinicalTrials.gov, the dose-escalation trial against semaglutide (NCT07639021)ClinicalTrials.gov, the first-in-human study (NCT06737536) and the other two phase 1 trialsNovo Nordisk Q3 2026 earnings call, November 4, 2026
What has happened recently
Nothing is approved and nothing is filed. The identity chain is solid: every trial of NNC0662-0419 carries an organization study ID beginning NN9662, and Novo's own trial pages serve the compound code under those IDs, so NN9662, Triple and NNC0662-0419 are one asset. The mechanism, by contrast, rests on a single sentence fragment. Novo's 2025 annual report phase 2 obesity table gives the description GLP-1/GIP/amylin and the phase progress 1 to 2, and its only prose on the asset is that a phase 1b/2 trial investigating Triple in people with obesity was initiated. Two absences on that same page are informative: the report never calls it a triple agonist, unimolecular, a single molecule, a peptide or a co-formulation, and Novo does use exactly that vocabulary for its neighbors, describing zenagamtide as unimolecular and CagriSema as a fixed-dose combination. **Novo has not restated the receptor profile anywhere in 2026.** In the November 4, 2026 third-quarter materials the compound codes do not appear at all and the milestone table lists UBT251 with the label tri-agonist beside Triple with no label, no product name and no targets. There is also a phase inconsistency worth knowing: the annual report's prose says phase 1b/2 while the registry registers the obesity dose-finding trial as phase 2 and the table shows a 1 to 2 progression.
You can compare this against the whole library, or read how to check a seller.
What else is like NN9662 (Triple)?
Others in Amylin analogs, side by side.If you're weighing NN9662 (Triple), it's worth reading PF-08653945 (MET-233i), Pramlintide, and Cagrilintide in the same class.
Novo's other triple agonist, the one that hits amylin.
- Dose
- No dose disclosed in any trial record
- How often
- Once weekly
An experimental amylin shot designed for monthly dosing, now in a 940-person phase 2b.
- Dose
- 0.15 up to 1.2 mg weekly (phase 1 doses)
- How often
- Weekly; monthly dosing under test
An approved mealtime shot used with insulin to blunt blood-sugar spikes and hunger.
- Dose
- 0.015 up to 0.12 mg per dose (start low, increase slowly)
- How often
- With meals
A weekly fullness-hormone shot, often paired with semaglutide for bigger loss.
- Dose
- 0.3 up to 4.5 mg per dose (start low, increase slowly)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Novo Nordisk annual report 2025, innovation and therapeutic focus(2025)The only public statement of this compound's mechanism, and it is one phrase. The phase 2 obesity table reads Triple, NN9662, obesity, GLP-1/GIP/amylin, phase progress 1 to 2, and the only prose is that a phase 1b/2 trial investigating Triple in people with obesity was initiated. What the page does not say matters as much: it never calls the compound a triple agonist, unimolecular, a single molecule, a peptide or a co-formulation, while using unimolecular for zenagamtide and fixed-dose combination for CagriSema on the same page. The same report separately describes UBT251 as a GLP-1/GIP/glucagon triple receptor agonist, and that is the contrast this card turns on.
- ClinicalTrials.gov, the phase 2 obesity dose-finding trial (NCT07184632)(2026)Organization study ID NN9662-8110. Safety, tolerability and efficacy of once-weekly NNC0662-0419 in people with overweight or obesity. Phase 2, active and not recruiting, 224 participants actual, started October 1, 2025, primary completion estimated December 14, 2026. Randomized and quadruple masked in three parts: multiple ascending dose, dose-range finding, and a two-week escalation. Secondary outcomes include the proportions reaching 5, 10, 15, 20 and 25% weight reduction at week 36. Two things to note: the record names one investigational product with one matched placebo rather than a combination, and it states no dose level and no mechanism.
- ClinicalTrials.gov, the phase 2 type 2 diabetes dose-finding trial (NCT07415954)(2026)Organization study ID NN9662-8160. The largest and most geographically spread trial in the program, and the one missing from coverage of it. Phase 2, recruiting, 270 participants estimated, 63 sites across Croatia, Hungary, Japan, Poland, Portugal, Slovakia, South Korea, Spain, Thailand and the United States, started April 17, 2026 with primary completion estimated September 3, 2027. Semaglutide is the active comparator. The primary outcome is change in HbA1c at weeks 16, 28 and 40, with weight, fasting glucose, waist, lipids and kidney measures secondary. Its existence also explains why the 2025 annual report has no diabetes row for this compound: the diabetes trial started after that report was published.
- ClinicalTrials.gov, the dose-escalation trial against semaglutide (NCT07639021)(2026)Organization study ID NN9662-8649. Different escalation regimens for NNC0662-0419 in obesity. Phase 2, active and not recruiting, 233 participants actual, started June 9, 2026, primary completion estimated June 14, 2027, 25 sites stated against 24 itemized in the record. Semaglutide and a matched placebo for each drug make it double-dummy. The point easiest to misread: the primary outcome is the number of gastrointestinal adverse events from week 0 to 39, and body weight change is secondary, so a trial that looks like a head-to-head against semaglutide is a tolerability study.
- ClinicalTrials.gov, the first-in-human study (NCT06737536) and the other two phase 1 trials(2026)Organization study ID NN9662-7694. Single and multiple ascending doses, phase 1, 100 participants actual, started December 18, 2024 and completed July 26, 2025, at one site. Five single dose levels and four weekly dose levels, with no amounts stated, and no results section posted. Two further phase 1 studies exist: a 100-participant comparison of exposure in Japanese, Chinese and non-Asian participants (NN9662-8159), completed October 31, 2025 and also with no results posted, and a 41-participant study of the effect on an oral contraceptive's absorption and on gastric emptying (NN9662-8158), the record that shows dosing through a pen injector. Across all six trials roughly 770 people have been dosed and nothing has been reported.
- Novo Nordisk Q3 2026 earnings call, November 4, 2026(2026)Read as a transcript published by a financial site rather than on Novo's own domain. The most useful sentence anywhere for keeping the two triples apart: management said the company anticipates phase 1/2 results for both of its tri-agonists in the first half of 2027, and that these include UBT251 targeting the receptors of GLP-1, GIP and glucagon, and its internal triple molecule targeting GLP-1, GIP and amylin. Management also said the coming readouts will show the adverse event and tolerability profile of the two drugs. Note that this is the one place a Novo representative calls the internal program a molecule, suggestive of a single compound without being a statement of molecular format.
Beyond these, 6 records are indexed. Browse the records